http://nano.suda.edu.cn/lz/

The founder of InnoBM, Dr. Zhuang Liu, has been working in the field of biomaterials for decades. His research team has pioneered in the development of biomaterials and nanomedicine strategies for biomedical imaging, drug delivery, and novel cancer therapies. One particular research direction of his team is to develop innovative biomaterials to boost the efficacy of cancer immunotherapy. Dr. Liu has authored over 300 peer-reviewed papers, many of which were published on leading academic journals such as Nature Biomedical Engineering, Nature Nanotechnology, Nature Communications, Science Advances, PNAS and etc. His publications have received a total citation of > 70,000 times and an H-index at 137. His research has already generated considerable international impacts in the related communities.

Based on the original research from Dr. Zhuang Liu’s team, the major mission of InnoBM is to develop novel therapeutics that can induce in situ vaccination after local administration into tumors. The idea is to locally deliver multi-functional therapeutics into tumors, kill tumor cells to release tumor antigens (e.g. via inducing immunogenic cell death), activate immune cells especially antigen presenting cells, and subsequently trigger tumor-specific immune responses.  Such a technology would realize systemic therapeutic responses via local drug administration, via eliciting robust antitumor immunity. Our novel therapeutics could be used alone, or synergize with immunotherapeutics currently used in clinic, to achieve the optimal therapeutic outcome in inhibiting tumor metatheses and recurrence.